Últimas noticias sobre iCoreConnect (NASDAQ:ICCT) Bolsa

iCoreConnect

iCoreConnect Inc develops and markets secure cloud-based HIPAA compliant software services focused on compliance, workflow/productivity, and electronic health records systems. Its core services technology can be adopted to other vertical markets that require a high degree of secure data communication, such as the legal, financial, and education fields. It markets secure HIPAA compliant cloud-based software as a service (SaaS) offering under the names of iCoreExchange, iCoreCodeGenius, iCoreSecure, iCoreMD, iCoreDental, iCoreMobile, iCoreHuddle, iCoreRx, iCorePDMP, iCoreEPCS, and iCorePay. The company's software is sold under annual recurring revenue subscriptions. The company has a single reporting segment for reporting purposes focused on the North American market.

Acciones que se mueven

ARHS

BASE

CAPR

CDNA

CTOR

DGLY

HLMN

ICCT

NTHI

TILE

Xos sorprende al mercado con sólidos resultados en 2024 y hace subir sus acciones antes de la apertura. Descubre más movimientos aquí.

Acciones de Xos (XOS) suben alrededor de un 9%; Aquí están 20 acciones que se mueven en el premercado de EE. UU.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AAMI

ACEL

AXON

CLIK

ENVB

FLYW

HCTI

LBTYK

LMND

NAMS

PITA

PRCH

SMCI

ZoomInfo sorprende con resultados mejores de lo esperado y sus acciones suben un 19,6%. Descubre qué otras acciones se están moviendo hoy.

Acciones de ZoomInfo se disparan un 20%; 20 acciones que se están moviendo en el premercado de EE.UU.

iCoreConnect Inc

NOV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOV#NYSE">NOV</a>) sees Q2 sales of $2.171 billion-$2.238 billion vs $2.18 billion analyst estimate.

Guidance

NOV Sees Q2 Sales $2.171B-$2.238B vs $2.18B Est

UBS analyst Thomas Wadewitz maintains Saia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIA#NASDAQ">SAIA</a>) with a Buy and lowers the price target from $422 to $305.

Price Target

Analyst Ratings

SAIA

UBS Maintains Buy on Saia, Lowers Price Target to $305

National Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRC#NASDAQ">NRC</a>) reported quarterly earnings of $0.25 per share. This is a 7.41 percent decrease over earnings of $0.27 per share from the same period last year. The company reported $33.55 million in sales this quarter. This is a 4.99 percent decrease over sales of $35.31 million the same period last year.

Earnings

National Research Q1 EPS $0.25 Down From $0.27 YoY, Revenue $33.55M Down From $35.31M YoY

NOV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOV#NYSE">NOV</a>) reported quarterly earnings of $0.19 per share which missed the analyst consensus estimate of $0.26 by 26.92 percent. This is a 36.67 percent decrease over earnings of $0.30 per share from the same period last year. The company reported quarterly sales of $2.10 billion which met the analyst consensus estimate. This is a 2.41 percent decrease over sales of $2.15 billion the same period last year.

Earnings Misses

NOV Q1 EPS $0.19 Misses $0.26 Estimate, Sales $2.10B Inline

UBS analyst Dennis Geiger maintains Starbucks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) with a Neutral and lowers the price target from $105 to $90.

SBUX

UBS Maintains Neutral on Starbucks, Lowers Price Target to $90

Krystal Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRYS#NASDAQ">KRYS</a>) has outperformed the market over the past 5 years by 15.4% on an annualized basis producing an average annual return of 29.66%. Currently, Krystal Biotech has a market capitalization of $4.89 billion. 
Buying $100 In KRYS: If an investor had bought $100 of KRYS stock 5 years ago, it would be worth $359.67 today based on a price of $169.73 for KRYS at the time of writing.
<h3>Krystal Biotech's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745876711_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

KRYS

Here's How Much You Would Have Made Owning Krystal Biotech Stock In The Last 5 Years

UBS analyst Lloyd Walmsley maintains Booking Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKNG#NASDAQ">BKNG</a>) with a Buy and lowers the price target from $5960 to $5557.

BKNG

UBS Maintains Buy on Booking Holdings, Lowers Price Target to $5557

Teradyne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>) is looking for Q2 GAAP EPS of $0.35-$0.48 vs $0.51 analyst estimate..

Teradyne Sees Q2 GAAP EPS $0.35-$0.48 vs $0.51 Est

UBS analyst Jay Sole maintains Carter's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRI#NYSE">CRI</a>) with a Neutral and lowers the price target from $37 to $32.

UBS Maintains Neutral on Carter's, Lowers Price Target to $32

<a href="https://www.bloomberg.com/news/articles/2025-04-28/boeing-removed-from-credit-watch-by-s-p-in-turnaround-boost?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-04-28/boeing-removed-from-credit-watch-by-s-p-in-turnaround-boost?embedded-checkout=true</a>

General

'Boeing Removed From Credit Watch by S&P in Turnaround Boost'- Bloomberg

UBS analyst Stephen Ju maintains Expedia Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>) with a Neutral and lowers the price target from $194 to $170.

EXPE

UBS Maintains Neutral on Expedia Group, Lowers Price Target to $170

German American Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GABC#NASDAQ">GABC</a>) reported quarterly earnings of $0.79 per share which beat the analyst consensus estimate of $0.66 by 19.7 percent. This is a 27.42 percent increase over earnings of $0.62 per share from the same period last year. The company reported quarterly sales of $81.41 million which beat the analyst consensus estimate of $79.56 million by 2.33 percent. This is a 33.87 percent increase over sales of $60.82 million the same period last year.

Earnings Beats

GABC

German American Bancorp Q1 Adj. EPS $0.79 Beats $0.66 Estimate, Sales $81.41M Beat $79.56M Estimate

UBS analyst Brian Meredith maintains Goosehead Insurance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GSHD#NASDAQ">GSHD</a>) with a Buy and lowers the price target from $145 to $140.

GSHD

UBS Maintains Buy on Goosehead Insurance, Lowers Price Target to $140

UBS analyst Ashwani Verma maintains Harmony Biosciences Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRMY#NASDAQ">HRMY</a>) with a Buy and lowers the price target from $55 to $48.

HRMY

UBS Maintains Buy on Harmony Biosciences Hldgs, Lowers Price Target to $48

Linkbancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNKB#NASDAQ">LNKB</a>) reported quarterly earnings of $0.20 per share which missed the analyst consensus estimate of $0.24 by 16.67 percent. This is a 25 percent increase over earnings of $0.16 per share from the same period last year. The company reported quarterly sales of $39.09 million which beat the analyst consensus estimate of $32.48 million by 20.34 percent. This is a 46.88 percent increase over sales of $26.61 million the same period last year.

LNKB

Linkbancorp Q1 Adj. EPS $0.20 Misses $0.24 Estimate, Sales $39.09M Beat $32.48M Estimate

UBS analyst Stephen Ju maintains Airbnb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) with a Neutral and lowers the price target from $160 to $138.

ABNB

UBS Maintains Neutral on Airbnb, Lowers Price Target to $138

Broadway Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BYFC#NASDAQ">BYFC</a>) reported quarterly losses of $(0.14) per share. This is a 600 percent decrease over losses of $(0.02) per share from the same period last year. The company reported $8.33 million in sales this quarter. This is a 6.42 percent increase over sales of $7.83 million the same period last year.

BYFC

Broadway Financial Q1 EPS $(0.14) Down From $(0.02) YoY, Sales $8.33M Up From $7.83M YoY

UBS analyst Ashwani Verma maintains ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) with a Buy and lowers the price target from $25 to $22.

ACAD

UBS Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $22

UBS analyst Ashwani Verma maintains Alkermes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALKS#NASDAQ">ALKS</a>) with a Neutral and lowers the price target from $38 to $33.

ALKS

UBS Maintains Neutral on Alkermes, Lowers Price Target to $33

WIIM

OKTA

Okta shares are trading higher after the company announced it will replace Berry Global Group in the S&P Midcap 400, effective before the opening of trading on Thursday, May 1

Comments

iCoreConnect

Noticias

Últimas noticias sobre iCoreConnect (NASDAQ:ICCT) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL